SV

Street Verdict

Analyst Scorecard

A record of what Jefferies Analysis said publicly, with the source. Not advice.

“Upgraded Gland Pharma to 'buy' from 'hold' on August 11, setting a target of ₹3,350 per share, which implies a 17.9% upside from current levels. The upgrade indicates a positive view on the stock's potential.”

Jefferies Analysis’s track record (trackable calls only): 153 graded calls · 95% CI 37–53%

Gland PharmaBullishCalled 20 Aug 2026Graded 21 Nov 2026
Verdict:HIT

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹3,350, as stated.

Window: 12 months, the default when no time frame is stated.

The target ₹3,350 was reached on a close. Hit.

The grader’s working: R4 TARGET_CALL: entered ₹2819.3 on 2026-08-21 (next trading session's close); target ₹3350 reached at close ₹3385.9 on 2026-11-16. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.

How it played out

How this is worked out
Time to target
The target was reached on a close 58 trading sessions (87 calendar days) after the entry.
Worst close against it
The closing price went as far as 0.63% against the call before the target was reached, measured from the entry price. Closing prices only; an intraday dip is never counted.

From the entry the grade used, on closing prices. This is a record of one past call and is not advice.

Tracking Gland Pharma since this call

1-year tracking window
Read the original articleSee Jefferies Analysis’s full track record